Coherus BioSciences (Nasdaq: CHRS) has notified the US markets authority that it will terminate a collaboration with Shanghai-based Junshi Biosciences (HKEX: 1877) related to an anti-TIGIT candidate.
The Californian firm, which is well known as a developer of biosimilars, agreed a major deal with Junshi in early 2021, including an option on certain immuno-oncology drug candidates.
Just a couple of years after paying $35 million to exercise an option on one such candidate, CHS-006, Coherus has decided to change course.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze